<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483726</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0340</org_study_id>
    <nct_id>NCT04483726</nct_id>
  </id_info>
  <brief_title>Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)</brief_title>
  <acronym>DIPLOMA</acronym>
  <official_title>Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA): a Pan-European, Randomized Controlled, Multicenter, Patient Blinded, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To compare MIDP with ODP regarding radical resection rate for pancreatic ductal
      adenocarcinoma (PDAC) in the pancreatic body or tail.

      Study design: A pan-European, randomized controlled, multicenter, patient-blinded
      non-inferiority trial. This protocol was designed according to the SPIRIT guidelines1.
      Pathologists judging the primary endpoint will be blinded for the surgical approach (MIDP vs
      ODP). A blinded adjudication committee will assess all endpoints.

      Study population: Two groups of 129 patients (258 in total) with an indication for elective
      distal pancreatectomy with splenectomy because of proven or highly suspected PDAC.

      Intervention: Minimally invasive distal pancreatectomy (either laparoscopic or
      robot-assisted)

      Control: Open distal pancreatectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Several systematic reviews have suggested superior short term outcomes after
      minimally invasive distal pancreatectomy (MIDP) as compared to open distal pancreatectomy
      (ODP) for benign and pre-malignant disease. In the literature and in a recent pan-European
      survey, about one third of pancreatic surgeons expressed concerns regarding the oncologic
      safety (i.e. radical resection, lymph node retrieval and survival) of MIDP in pancreatic
      cancer. Most surgeons stated that a randomized trial assessing oncologic safety in MIDP vs
      ODP for pancreatic cancer is needed.

      Objective: To compare MIDP with ODP regarding radical resection rate for pancreatic ductal
      adenocarcinoma (PDAC) in the pancreatic body or tail.

      Study design: A pan-European, randomized controlled, multicenter, patient-blinded
      non-inferiority trial. This protocol was designed according to the SPIRIT guidelines1.
      Pathologists judging the primary endpoint will be blinded for the surgical approach (MIDP vs
      ODP). A blinded adjudication committee will assess all endpoints.

      Study population: Two groups of 129 patients (258 in total) with an indication for elective
      distal pancreatectomy with splenectomy because of proven or highly suspected PDAC.

      Intervention: Minimally invasive distal pancreatectomy (either laparoscopic or
      robot-assisted)

      Control: Open distal pancreatectomy

      Main study parameters/endpoints: Primary outcome is the microscopically radical (R0, &gt;1mm)
      resection rate. Main secondary outcomes are survival, lymph node retrieval, intraoperative
      outcomes (such as blood loss, operative time and conversion), postoperative outcomes (such as
      complications, time to functional recovery and hospital stay) and quality of life
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 25, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>microscopically radical resection rate</measure>
    <time_frame>1 day</time_frame>
    <description>R0, &gt;1mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>1 year</time_frame>
    <description>Date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>2 years</time_frame>
    <description>Date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>3 years</time_frame>
    <description>Date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymph node retrieval</measure>
    <time_frame>1 day</time_frame>
    <description>Tumor positive lymph nodes retrieved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>1 day</time_frame>
    <description>Operative time from first incision to closure of the abdomen, minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>1 day</time_frame>
    <description>Intraoperative blood loss, mL (suction canister and weight of gauzes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative outcomes</measure>
    <time_frame>1 day</time_frame>
    <description>Total duration of the procedure, minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative outcomes</measure>
    <time_frame>1 day</time_frame>
    <description>Major complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>specimen size</measure>
    <time_frame>1 day</time_frame>
    <description>Tumor size, mm;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specimen length</measure>
    <time_frame>1 day</time_frame>
    <description>Specimen length, mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>margin</measure>
    <time_frame>1 day</time_frame>
    <description>Distance from tumor to transectionanterior and posterior margin mm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>MIDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>minimally invasive distal pancreatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ODP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>open distal pancreatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>minimally invasive distal pancreatectomy</intervention_name>
    <description>Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted)</description>
    <arm_group_label>MIDP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>open distal pancreatectomy</intervention_name>
    <description>open distal pancreatectomy</description>
    <arm_group_label>ODP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years;

          -  Elective indication for distal pancreatectomy for proven or suspected* PDAC;

          -  Upfront (without induction / down-sizing radio- and/or chemotherapy) resectable PDAC
             in the pancreatic body or tail**;

          -  The tumor can be radically resected via both minimally invasive or open surgery
             according to the local treating team***;

          -  The patient is fit to undergo both open and minimally invasive distal pancreatectomy

        Exclusion Criteria:

          -  ASA &gt;3 (see appendix 17.3.2);

          -  A medical history of chronic pancreatitis (according to the M-ANNHEIM criteria, see
             Appendix for detailed definition);

          -  Second malignancy necessitating resection during the same procedure;

          -  Distant metastases (M1) including involved distant lymph nodes;

          -  Tumor involvement or abutment of major vessels (celiac trunk*, mesenteric artery or
             portomesenteric vein);

          -  Pregnancy;

          -  Participation in another study with interference of study outcomes.

          -  Cystic lesion having undergone malignant transformation

               -  the celiac trunk should be 5mm clear from tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François Régis SOUCHE</last_name>
    <phone>+334 67 33 70 72</phone>
    <email>fr-souche@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillemette TACONNET</last_name>
    <phone>+334 67 33 55 73</phone>
    <email>g-taconnet_decker@chu-montpellier.fr</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

